Antagonists of Wnt-inhibitors
Sclerostin (SOST) and dickkopf-1 (dkk1) are endogenous inhibitors of the canonical Wnt/β–catenin pathway specific to bone. In the presence of these inhibitors, the osteoblast precursors are not exposed to a Wnt signal, so that β–catenin is degraded and osteoblast differentiation and recruitment is stopped. Antibodies directed against sclerostin or dickkopf-1, should therefore have bone anabolic properties.